Summary
| Title: | Bcl_2-Navitoclax Analog (with Indole) Complex |
| Citation: | Souers, A.J.,Leverson, J.D.,Boghaert, E.R.,Ackler, S.L.,Catron, N.D.,Chen, J.,Dayton, B.D.,Ding, H.,Enschede, S.H.,Fairbrother, W.J.,Huang, D.C.,Hymowitz, S.G.,Jin, S.,Khaw, S.L.,Kovar, P.J.,Lam, L.T.,Lee, J.,Maecker, H.L.,Marsh, K.C.,Mason, K.D.,Mitten, M.J.,Nimmer, P.M.,Oleksijew, A.,Park, C.H.,Park, C.M.,Phillips, D.C.,Roberts, A.W.,Sampath, D.,Seymour, J.F.,Smith, M.L.,Sullivan, G.M.,Tahir, S.K.,Tse, C.,Wendt, M.D.,Xiao, Y.,Xue, J.C.,Zhang, H.,Humerickhouse, R.A.,Rosenberg, S.H.,Elmore, S.W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. NAT.MED. (N.Y.), 19:202-208, 2013 PubMed: 23291630DOI: 10.1038/nm.3048 |
| Experimental method: | X-RAY DIFFRACTION (2.07 Å) |
| Deposition date: | 2013-07-29 |
| Release date: | 2013-08-14 |
| Obsoletion date: | 2014-01-29 |
Timeline
Downloads
| File format | File name (file size) | ||
| PDBx/mmCIF | 4lxe.cif.gz Display(74.95 KB) 4lxe.cif | ||
| PDBML | all | 4lxe.xml.gz Display(100.26 KB) 4lxe.xml | |
| PDB | pdb4lxe.ent.gz Display(61.28 KB) pdb4lxe.ent | ||
| Structure factors | r4lxesf.ent.gz Display(725.04 KB) r4lxesf.ent | ||
